Compare Roundhill Magnificent Seven ETF (MAGS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Novavax Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $73.6 (market cap $5.78B), while Novavax Inc trades at $12.04 (market cap $1.82B). The key difference: Roundhill Magnificent Seven ETF is far larger — about 3.2× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 4,410,665). Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Novavax Inc for 59 Days on average.
| MAGS | NVAX | |
|---|---|---|
Market Cap | $5.78B | $1.82B |
Volume | 4,410,665 | 6,198,505 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $12.56 |
52-Week Low | $55.39 | $6.22 |
Typical Hold Time | 36 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $73.63, down slightly by 0.08% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the broader market in 2026 with only 2% year-to-date gains. Recent news highlights ongoing investor debate about the Magnificent Seven's leadership role amid shifting AI investment trends.
The ETF faces near-term pressure from underperformance versus the S&P 500 but maintains long-term growth potential through diversified tech exposure. Key risks include concentration in seven stocks and market rotation away from mega-caps, while the bullish technical setup suggests potential for near-term recovery if AI momentum continues.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
